It is unclear how human immunodeficiency virus (HIV) type 1-specific immune responses in exposed seronegative (ESN) individuals differ from those in HIV-1-infected subjects. By use of overlapping peptides spanning Gag, Tat, Nef, Vif, Vpr, and Vpu, peripheral blood mononuclear cells from ESN individuals, their seropositive (SP) partners, and unexposed seronegative control subjects were screened for interferon-g production. Responses were more frequent (95.7% vs. 20%), of a higher magnitude (9-fold), and of wider breadth (median number of peptides recognized, 18 vs. 2.5) in SP than in ESN individuals. Peptides recognized by ESN individuals were less frequently recognized by their SP partners. SP subjects infrequently recognized peptides from Vif, and such responses were subdominant; among ESN individuals, this HIV-1 protein was most frequently recognized. Immunodominant peptides recognized by SP subjects tended to be from relatively conserved regions, whereas peptides recognized by ESN individuals were associated with slow disease progression.
It is increasingly clear that some individuals do not develop established HIV-1 infection, as evidenced by persistent seronegativity despite repeated sexual exposure to the virus [1] [2] [3] [4] [5] [6] [7] [8] [9] . This has led to the concept of resistance to HIV-1. It is postulated that acquired immunity plays a role in this resistance. If this is the case, the immunological evaluation of these individuals is important to the design of prophylactic HIV-1 vaccine.
Studies of these apparently resistant individuals, who are referred to as exposed seronegative (ESN) individuals, have documented the presence of HIV-1-specific CD8 + cytotoxic T lymphocyte (CTL) [1-7, 10, 11, 13] and CD4 + helper T lymphocyte (HTL) responses [3, 5, 6, 12] . HIV-1-specific CD4 + HTLs are necessary for the induction of the effective function of specific CD8 + CTLs [14] [15] [16] , which play an important role in con-trolling viral replication [16] [17] [18] . It has been postulated that the combined presence of HIV-1-specific CD4 + and CD8 + T cells in ESN individuals effectively controls HIV-1 replication and results in an abortion of infection. Such responses may be more prevalent and of a higher magnitude and breadth in HIV-1-infected subjects than in ESN individuals [1, 2, 11, 13, 19 ] and yet, ultimately, do not protect HIV-1-infected subjects from progression to AIDS [16, 20] . It thus remains unclear how such responses contribute to resistance from infection in ESN individuals. We postulate that if, indeed, HIV-1-specific cellular immune responses in ESN individuals are a feature of protective immunity, this is not because they are more prevalent, of a higher magnitude, or of a wider breadth than in HIV-1-infected subjects but because of preferential epitope recognition [11, 19] . The objective of our study was therefore to investigate differences in peptide recognition between ESN individuals and their infected partners. Peripheral blood mononuclear cells (PBMCs) were prepared from plasma obtained from ESN individuals, their seropositive (SP) partners, and seronegative individuals not exposed to HIV-1, who served as control subjects. Responses were evaluated in enzyme-linked immunospot (ELISpot) assays for interferon (IFN)-g secretion. Overlapping peptides spanning the HIV-1 proteins Gag, Tat, Nef, Vif, Vpr, and Vpu, were pooled according to predetermined matrices and used for stimulation.
We focused on using peptides from structural, regulatory, and accessory genes because, first, the response to a single HIV-1 peptide or a single protein is not predictive of the entire response within an individual, given that multiple HIV-1 peptides/proteins are recognized in every HIV-1-infected subject [21] [22] [23] and, also, possibly in ESN individuals. Second, recent data have suggested that CTL responses directed against the early expressed regulatory proteins Tat and Rev play a key role in the HIV-1-specific immune response, which is important in virus containment [24, 25] . Finally, infected subjects have shown responses toward the accessory proteins Vpr, Vpu, and Vif. In fact, Vpr was preferentially targeted by CTLs during HIV-1 infection [26] . It is therefore important to determine whether PBMCs from ESN individuals also recognize these proteins.
SUBJECTS, MATERIALS, AND METHODS
The Science and Ethics committee of the Uganda Virus Research Institute granted approval for the study in December 2000. This was renewed in December 2002. The study is being conducted within established institutional ethical guidelines governing research involving human subjects. All study participants provided written consent for their participation after being provided with information about the study's aims and about HIV prevention and transmission and after being counseled.
Study population. A cohort was established of 28 HIV-1-serodiscordant couples with a history of frequent penetrative vaginal intercourse (mean frequency, twice a week), with some unprotected sexual contact occurring in the weeks or days immediately before enrollment. Fifteen couples reported never having used condoms during sex, whereas 9 couples reported irregular condom use in the 12 months before enrollment. Although the 4 remaining couples reported using condoms during all sexual contacts, they were still enrolled, because there was evidence of ongoing exposure, including a disclosure of unprotected sex during individual interviews and pregnancy.
It was not possible to accurately determine the duration of exposure to HIV-1 among ESN individuals, because the dates of seroconversion among their SP partners were unknown. However, it was evident that exposure to HIV-1 had been ongoing, because unprotected sexual contact occurred during periods of known serodiscordance. As control subjects, 12 HIV-1-seronegative individuals with low-risk sexual behavior, no history of sexually transmitted diseases, and no history suggestive of exposure to HIV-1 infection were enrolled from among university students and laboratory staff.
CD4
+ T cell count, HIV-1 infection status, and plasma virus load. A commercial kit (FACScount; BD Immunocytometry Systems) was used to determine CD4 + and CD8 + T cell counts from whole blood mixed with EDTA, according to the manufacturer's instructions.
Plasma was prepared by centrifugation of whole blood at 1000 g for 3 min; the plasma was then used to determine HIV-1 serostatus by first performing 2 of the following rapid tests, according to the manufacturer's instructions: Uni-Gold (Trinity Biotech), Abbot Determine (Abbot Diagnostics), or Genie II (BioRad), followed by confirmation of the results by testing the same sample using the Recombigen HIV-1/HIV-2 EIA (Cambridge Diagnostics) or Wellcozyme HIV (Abbot Diagnostics) recombinant test kits. If seropositive results were obtained, the plasma was assayed for HIV-1 RNA using the Amplicor HIV-1 monitor test kit (version 1.5; Roche Diagnostics).
Preparation of PBMCs. PBMCs were prepared from freshly drawn sodium-heparinized blood by Ficoll-Hypaque (Sigma) density-gradient centrifugation. After washing twice with R 0 medium (RPMI 1640 that contained 100 U penicillin/mL, 100 mg streptomycin/mL, and 2 mmol l-glutamine/L), the PBMCs were resuspended in freezing medium that consisted of 10% dimethyl sulphoxide and 90% fetal bovine serum (both from Sigma), frozen slowly, and stored at Ϫ80ЊC before transfer to liquid nitrogen. One day before use, they were thawed, washed twice with R 0 , and incubated overnight in R 10 (10% human AB serum or 10% fetal bovine serum in R 0 ) at 37ЊC in 5% CO 2 .
Peptides. Peptide sets were obtained from the National Institutes of Health AIDS Research and Reference Reagent Program and consisted of a total of 174 overlapping peptides. They spanned the proteins Gag, Tat, Nef, Vif, Vpr, and Vpu. With the exception of the Gag peptides derived from clade A, all were based on clade B consensus sequences. The majority of Gag and Nef peptides were 20-mers overlapping by 10 aa, and the majority from Tat, Vif, Vpr, and Vpu were 15-mers overlapping by 11 aa. Peptides were pooled in matrices such that, within any given matrix, each peptide was represented in 2 different pools, which allowed the identification of a single peptide by responses to the 2 corresponding pools. The number of pools per matrix and the number of peptides per pool depended on the total number of peptides spanning each protein.
ELISpot assays. This assay was modified from a protocol described elsewhere [27] . Ninety-six-well hydrophobic polyvinyldene difluoride membrane-bottomed plates (MAIP S 45; Millipore) were coated with 10 mg anti-IFN-g monoclonal antibody (MAb)/mL (1-D1K, mouse IgG1; Mabtech) overnight at 4ЊC. After washing with R 0 , the plates were blocked with R 10 for 1 h at 37ЊC in 5% CO 2 . Pools of HIV-1 peptides (final concentration of each peptide, 7.1 mg/mL) were then added to appropriate wells, followed by PBMCs ( -cells/ 4 5 5 ϫ 10 3 ϫ 10 well). Phytohemagglutinin (PHA, final concentration, 5 mg/mL; Sigma) and R 10 were added to separate wells as positive and negative controls, respectively. Negative controls were run in triplicate, and the remainder was tested in single wells.
After overnight incubation at 37ЊC in 5% CO 2 , the plates were washed with 1ϫ PBS with 0.05% Tween-20 and incubated at room temperature in the dark for 1 h with 1 mg biotinylated anti-IFN-g MAb/mL (7-B6-1, mouse IgG1; Mabtech). After a third wash, the plates were incubated at room temperature in the dark for 1 h with 1 mg streptavidine-alkaline phosphatase conjugate/mL (Mabtech). A fourth wash step was performed, and 100 mL of nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate in 1ϫ development buffer (Biorad) was added. The plate was then incubated for up to 20 min at room temperature in the dark. After the development of spots, the plates' contents were discarded, and the plates were washed with tap water and air-dried. Numbers of spot-forming cells (sfc) were counted using an automated ELISpot reader (Zeiss).
To establish the reproducibility of this approach in our setting, we are currently repeating the assays, using the same protocol described above, on PBMCs frozen at the same time point (where available) and/or on PBMCs frozen at a consecutive time point. However, other investigators have shown that the matrix approach allows for a highly sensitive and specific detection of responses [21] .
Statistical analysis. For results from the ELISpot assays, wells with numbers of spots below twice the background value were assigned zero spot counts, as were ambiguous responses that involved responses to 1 peptide pool only. Descriptive analyses were performed. If not normally distributed, quantitative data were presented as medians and ranges and compared using the Mann-Whitney U test. Bivariate and multivariate analyses were performed, and statistical associations were determined at 95% confidence levels with 2-tailed significance. Spearman's r correlation coefficient at 2-tailed significance was used in bivariate correlations.
RESULTS

Study Population Characteristics
In 12 serodiscordant couples, the SP partner was male and the ESN partner was female, whereas, in 16 couples, the SP partner was female and the ESN partner was male. Table 1 shows the study population characteristics at the time of enrollment. Control subjects were significantly younger than the couples, but this was unavoidable, given the constraints of enrollment. There was no significant difference between SP and ESN individual in the number who had a history of sexually transmitted infections ( ; ) or the number of male subjects 2 x p 0.09 P p .767 who were circumcised ( ; ). CD8 + T cell 2 x p 0.05 P p .815 counts were significantly lower in ESN than in either SP or control individuals, which contrasts with other observations in similarly resistant individuals [9] .
Ten ESN (7 men and 3 women) and 13 SP (7 men and 6 women) individuals had been in a previous union with someone other than their current partner. Among this group of subjects, there were 5 of 10 ESN and 5 of 13 SP individuals whose previous partner had died from an HIV-1-related dis- ease. Thus, 5 ESN individuals had been exposed to at least 2 SP partners, and, in 5 SP subjects, there was a suggestion of successful transmission of their virus in the past.
All SP subjects were naive for antiretroviral drug therapy at enrollment. Three had plasma virus loads (pVLs) below the limit of detection of the assay (!400 copies/mL) and CD4 + T cell counts 1500 cells/mm 3 . During follow-up, 9 SP individuals began antiretroviral therapy, and there were 2 seroconversions among ESN individuals but none among control subjects. Thus, at the time of writing, the cohort consisted of 26 serodiscordant couples, 2 seropositive concordant couples, and 12 control subjects.
HIV-1 Antigen Stimulation of IFN-g Secretion by PBMCs
Responses are more prevalent in SP than in ESN individuals. Varying the threshold of sfc per 10 6 PBMCs that was considered to be a positive response had an effect on the number of subjects identified as having responses in the different groups (table 2) . The definition of a positive response adopted was at least twice the number of spots in the negative control well and at least 50 sfc per 10 6 PBMCs, after the subtraction of background in the presence of a PHA response. This decision was based on the observation that lower thresholds resulted in some control subjects being declared responders and that, for purposes of the reproducibility of responses, higher thresholds needed to be used. By use of these criteria, the proportion of subjects with positive responses was higher among SP (95.7%) than ESN (20%) individuals, whereas none (0%) were present among control subjects (table 2) .
Responses are of a higher magnitude in SP than in ESN individuals. The sum of spot counts in SP individuals was 8.9 times greater than that in ESN individuals and 73.3 times greater than that in control subjects. Responses are of greater breadth in SP than in ESN individuals. The majority of SP subjects had responses to 11 peptide, either from the same protein or from 11 protein, which is similar to the findings of other investigators [21] [22] [23] . The median number of peptides recognized by an SP subject was 18, and the median number of proteins was 3. One SP subject responded to peptides in gag only, whereas 2 responded to peptides in the accessory genes but not in gag. The rest recognized peptides in gag and at least 1 accessory gene. PBMCs from ESN individuals tended to recognize peptides confined to 1 protein, although samples from 2 to 6 ESN individuals recognized peptides from 11 protein-Vif, Vpr, and Vpu or Vif and Vpu. The median number of peptides recognized among the 6 ESN samples that showed responses was 2.5, and the median number of proteins was 1.
There was a variation in the proportion of individuals whose samples showed responses to the different proteins. Samples from SP subjects recognized peptides most frequently in Gag (87.0%), then Vif (72.2%), Nef (69.6%), Vpr (55.6%), Tat (17.4%), and Vpu (11.1%). The pattern among samples from ESN individuals was Vif (20.0%), Vpu (13.3%), Gag (9.5%), Vpr (6.7%), Nef (4.8%), and Tat (0%). Individual peptides were recognized at different frequencies. Among samples from ESN individuals, the majority of peptides were recognized only by a single individual. One peptide was recognized by 2 ESN samples: Vif-2, WQVMIVWQVDRMRIR (Vif 5-19) ( figure  1A ). The heterogeneity of peptides recognized by ESN samples was similar to observations made in other cohorts of ESN individuals [11] . Although some peptides were recognized by samples from 1 SP subject, most were targeted by samples from several SP subjects (figure 1B). The most frequently recognized peptide by SP samples was located in Gag p17: LRPGGKKK-YRLKHLVWASRE (10/23 [43.5%]) (Gag 21-40 p p17 [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . This represents a highly conserved region of the HIV-1 genome among published sequences (available at: http://www.hiv.lanl .gov/content/hiv-db/EPILIGN/EPI.html).
Differences in peptide recognition between samples from SP and ESN individuals. Of the total 174 peptides, samples from SP subjects recognized 152 (87.3%), and samples from ESN individuals recognized 30 (17.2%). All peptides in Gag and Vpr were recognized by at least 1 SP sample. The majority of peptides not recognized by SP samples were from Vif, with a few from Vpu. Three of 14 peptides from Vif not recognized by SP samples were recognized by ESN samples. In fact, 12 of 14 peptides recognized by ESN samples were not recognized by those from their SP partners. ESN samples recognized 22 of 152 peptides recognized by samples from all SP subjects. Significant correlations were not seen between the numbers of peptides recognized and autologous pVLs, CD4
+ , or CD8 + T cell counts among SP samples (data not shown).
Varying immunodominance among SP samples. Among SP subjects, there was a positive correlation between the frequency of recognition of pools of peptides and the median spot count. Pools of peptides that were more frequently recognized also generated higher magnitudes of response. This was not, however, the case for ESN samples ( figure 2A ). When individual proteins from which the pools of peptides had been derived were examined, the positive correlation in SP samples was maintained for Gag, Nef, Tat, and Vpr but not for Vif and Vpu. For the latter 2 proteins, there was a negative correlation ( figure 2B-F) . The correlations were statistically significant for Nef and Vif.
Continuous exposure before enrollment and the detection of responses among ESN individuals. The 6 ESN individuals whose samples responded to the peptides tested all reported 0% condom use before their enrollment. There was a statistically significant association between 0% condom use at enrollment and a positive response among ESN samples (
). All other parameters were not significantly 11.2 P p .0008 different between these 6 ESN and the other ESN samples: age ( ), frequency of sex ( ), years of union with P p .891 P p .533 SP partner ( ), CD4 + T cell count ( ), and SP P p .970 P p .104 partner's pVL ( ). The CD8 + T cell count was margin-P p .362 ally significant ( ). P p .051
DISCUSSION
With a soaring epidemic characterized by 5 million new infections in 2002 alone [28] , the need for an HIV-1 vaccine to complement existing intervention strategies is paramount. Important to the effort of HIV-1 vaccine development is the evaluation of HIV-1-specific immune responses in individuals who are apparently resistant to HIV-1 (ESN).
In our cohort, of the 28 HIV-1-seronegative subjects who had an HIV-1-infected partner and who engaged in frequent unprotected sex, 26 remained uninfected by the end of our monitoring period. It is unlikely that factors such as the HIV-1 coreceptor CCR5 D32 Ϫ/Ϫ mutation [8] , low amounts of virus involved in exposure [29] , and male circumcision [30] play a major role in protection in this population, given that the CCR5 D32 Ϫ/Ϫ mutation is very rare among African populations, the majority of the SP partners of the ESN individuals had high pVLs, and the majority of ESN men were uncircumcised (12 of the ESN individuals were women). We consider an adaptive immune response to be important, because this state of apparent resistance is analogous to observations in animal studies [31] .
The proportion of subjects with positive HIV-1-specific IFNg responses was 0% for control subjects, 20% for ESN individuals, and 95.7% for SP subjects. This pattern is similar to what other investigators have described [1, 2, 11, 13, 20] . The absence of responses among control subjects and their presence in ESN individuals and their SP partners suggest that some ESN individuals and most SP partners, but no control subjects, were in a state of HIV-1-specific immune activation.
The fact that not all ESN samples recognized the peptides could be because such responses are intermittent in ESN individuals [1, 6, 10] . Also, the detection of such responses may be dependent on continuous exposure [10, 11] , which was not the case in all ESN individuals in our study. Lending support to this notion was the significant statistical association between the presence of responses in ESN individuals and 0% condom use reported at enrollment. The frequency of antigen-specific T cells decreases substantially in the absence of continuous antigenic stimulation [32] . Therefore, the seeming absence of responses in some ESN samples could have been because of very low frequencies of HIV-1-specific T cells as a result of interruptions in exposure. More-sensitive assays may need to be used [7] .
It is probable that the quality of HIV-1-specific cellular immune responses, in terms of specific CD4 + T cell proliferation (efficient recruitment and T cell help) [33] and CD8 + T cell maturation and perforin expression (efficient killing) [34] [35] [36] , as opposed to only the quantity of specific IFN-g responses, is key in protecting ESN individuals from infection. This may explain the 9-fold lower magnitude of responses in ESN individuals than in SP subjects. The narrower breadth of responses in ESN individuals than in SP subjects also could be akin to the narrower breadth of specific responses observed in acute HIV-1 infection, which only broaden with prolonged in vivo viral exposure [37] .
Protection from HIV-1 infection could also potentially be explained by differing immunodominance between ESN in-dividuals and SP subjects [11] . This has already been implied by the differential CTL epitope recognition observed between acute and chronic HIV-1 infection [38] , which suggests that CTL epitopes that dominate in chronic infection may not play a part in the critical antiviral responses that are associated with the initial clearance of virus in acute infection. By extrapolation, ESN individuals might target epitopes that are critical for viral replication but are not frequently targeted by the immune system in SP individuals.
The results of our study support this hypothesis. ESN samples tended to recognize peptides that SP samples were unlikely to recognize. Furthermore, peptides from the proteins Vpr, Nef, and Gag were immunodominant in SP samples, and there was a tendency for peptides in Vif and Vpu to be recognized by ESN samples, whereas these were subdominant in SP. Sequences of the peptides recognized by ESN samples were compared with those of known sequences in the PubMed database using a protein-protein blast (available at: http://www.ncbi.nlm.nih.gov /blast/blast.cig). Results showed that 23 of 30 peptides recognized by ESN samples had complete or almost complete homology to sequences of HIV-1 strains previously described in HIV-1-infected individuals with a slow rate of disease progression: GGKW-SKSSVVGWPTVRERMR (Nef 2-21) and GWPTVRERMRRAE-PAADGVG (Nef 12-31) [ [41] . One of the Nef peptides, MENRWQVMIVW-QVDR (Nef 1-15) also showed homology with sequences associated with highly pathogenic strains [42] .
It is possible that the HIV-1-specific cellular responses detected in ESN samples may only be a result of exposure and not the cause of protection from HIV-1 infection. Because it is not ethically permissible to demonstrate this cause (HIV-1-specific cellular immune responses) and effect (protection from an established HIV-1 infection), corroborative evidence for their role can only be drawn from animal studies [31] . It is, however, noteworthy that peptides from both structural and accessory proteins were recognized by ESN samples. This suggests that the entire expressed HIV-1 genome, as opposed to only structural proteins, may be important in protection against HIV-1 infection. The design of prophylactic HIV-1 vaccine may not necessarily be best based on immunodominant peptides/ proteins in SP subjects, because these were less frequently recognized by ESN samples. Similarly, any evaluation of prophylactic vaccines should not only be based on the quantification of HIV-1-specific IFN-g responses but also on a multiplicity of parameters. Our future work is aimed at further detailed analyses of immune correlates that are potentially associated with protection in these ESN individuals.
